Document is current

Article History

Accepted: 4 August 2024

First Online: 28 August 2024

Declarations

:

: No funding was received for the preparation of this article.

: SR has served on an advisory board for Argenx, a company involved in the development of advanced therapies for myasthenia gravis; ML has received consultation fees from Octapharma, a company producing intravenous immunoglobulins, and from Novartis, Roche and Amgen, companies involved in biologics development; other authors do not have any conflicts of interest to declare in relation to this manuscript.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: Not applicable.

: HJ and SR proposed the outline for the review, SR, TP and MV performed the literature review and drafted the initial manuscript. HJ, ML, SR, TP and MV all critically reviewed the manuscript. All authors have read and approve the final submitted manuscript and agree to be accountable for the work.